Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase
Simon A. Hawley,1
Morgan D. Fullerton,2
Fiona A. Ross,1
Jonathan D. Schertzer,2
Cyrille Chevtzoff,1
Katherine J. Walker,1
Mark W. Peggie,3
Darya Zibrova,3
Kevin A. Green,1
Kirsty J. Mustard,1
Bruce E. Kemp,4
Kei Sakamoto,3,*
Gregory R. Steinberg,2,4
D. Grahame Hardie1,
Abstract:
Salicylate, a plant product, has been in medicinal use since ancient times. More recently, it has been replaced by synthetic derivatives such as aspirin and salsalate, both of which are rapidly broken down to salicylate in vivo. At concentrations reached in plasma after administration of salsalate or of aspirin at high doses, salicylate activates adenosine monophosphate–activated protein kinase (AMPK), a central regulator of cell growth and metabolism. Salicylate binds at the same site as the synthetic activator A-769662 to cause allosteric activation and inhibition of dephosphorylation of the activating phosphorylation site, threonine-172. In AMPK knockout mice, effects of salicylate to increase fat utilization and to lower plasma fatty acids in vivo were lost. Our results suggest that AMPK activation could explain some beneficial effects of salsalate and aspirin in humans.
1 Division of Cell Signalling and Immunology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, UK. 2 Divisions of Endocrinology and Metabolism, Department of Medicine, and Department of Biochemistry and Biomedical Sciences, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada. 3 Medical Research Council Protein Phosphorylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, UK. 4 St. Vincents Institute of Medical Research and Department of Medicine, University of Melbourne, 41 Victoria Parade, Fitzroy, Vic 3065 Australia.
* Present address: Nestlé Institute of Health Sciences Société Anonyme, Campus École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.
To whom correspondence should be addressed: E-mail: d.g.hardie{at}dundee.ac.uk
The editors suggest the following Related Resources on Science sites:
In Science Magazine
PERSPECTIVES
Reuben J. Shaw and Lewis C. Cantley (18 May 2012) Science336 (6083), 813.
[DOI: 10.1126/science.1223140] |Summary »|Full Text »|PDF »
In Science Signaling
EDITORS' CHOICE
L. Bryan Ray (22 May 2012) Sci. Signal.5 (225), ec145.
[DOI: 10.1126/scisignal.2003239] |Abstract »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Prevention and Intervention Trials for Colorectal Cancer.
M. Komiya, G. Fujii, M. Takahashi, M. Iigo, and M. Mutoh (2013)
Jpn. J. Clin. Oncol.
|Abstract »|Full Text »|PDF »
Duration of rise in free fatty acids determines salicylate's effect on hepatic insulin sensitivity.
S. Pereira, W. Q. Yu, M. E. Frigolet, J. L. Beaudry, Y. Shpilberg, E. Park, C. Dirlea, B. L. G. Nyomba, M. C. Riddell, I. G. Fantus, et al. (2013)
J. Endocrinol.
217, 31-43
|Abstract »|Full Text »|PDF »
Inflammation during obesity is not all bad: evidence from animal and human studies.
J. Ye and O. P. McGuinness (2013)
Am J Physiol Endocrinol Metab
304, E466-E477
|Abstract »|Full Text »|PDF »
The Corepressor NCoR1 Antagonizes PGC-1{alpha} and Estrogen-Related Receptor {alpha} in the Regulation of Skeletal Muscle Function and Oxidative Metabolism.
J. Perez-Schindler, S. Summermatter, S. Salatino, F. Zorzato, M. Beer, P. J. Balwierz, E. van Nimwegen, J. N. Feige, J. Auwerx, and C. Handschin (2012)
Mol. Cell. Biol.
32, 4913-4924
|Abstract »|Full Text »|PDF »
Targeting the IKK{beta}/mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer.
C.-T. Chen, Y. Du, H. Yamaguchi, J.-M. Hsu, H.-P. Kuo, G. N. Hortobagyi, and M.-C. Hung (2012)
Mol. Cancer Ther.
11, 2212-2221
|Abstract »|Full Text »|PDF »
Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning.